No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC
In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Heart Failure Risk Lingers Long After Chemotherapy, Regardless of Dose
(MedPage Today) -- Anthracycline users with breast cancer or lymphoma had an upfront risk of congestive heart failure (CHF) that persisted during long-term follow-up in a population-based case-control study. The cumulative incidence of new-onset... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 3, 2023 Category: Cardiology Source Type: news

FDA OKs Sacituzumab Govitecan for HR+ Metastatic Breast Cancer FDA OKs Sacituzumab Govitecan for HR+ Metastatic Breast Cancer
Investigators reported an overall survival benefit of 3.2 months versus single agent chemotherapy in previously treated patients.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Chemotherapy workers face risks, reduced with safe handling
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2019/3/science-highlights/chemotherapy/thumb863843.jpg?itok=RIqv1cAv" /><br /><p>Analysis finds moderate level of evidence that workplace exposure is associated with increased risk of miscarriage and genetic damage</p> (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news

Mesothelioma Treatment Uses Natural Immune Cells
This study provides support for the clinical evaluation of this IL2-based delivery system,” the authors wrote. Continued research with IL2 treatments in humans could lead to a new standard for mesothelioma therapy. Using Cytokines Increases Effectiveness Cytokine factories are delivery systems that invoke innate immune cells to fight tumors. Each drug “factory” consists of thousands of drug-producing cells contained in a microscopic gel-like bead. The study investigators used mice to model the efficacy of IL2 cytokine factories. “The rapid clinical course of malignant mesothelioma necessitates the ...
Source: Asbestos and Mesothelioma News - February 1, 2023 Category: Environmental Health Authors: Amy Edel Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news

Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemo Improves Colon Cancer Outcomes
WEDNESDAY, Feb. 1, 2023 -- Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy is safe and effective for operable colon cancer, without increasing perioperative morbidity, according to a study published online Jan. 19 in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2023 Category: Pharmaceuticals Source Type: news

Quality of Life Predicts Chemo Tolerance in Early Breast Cancer Quality of Life Predicts Chemo Tolerance in Early Breast Cancer
Fatigue and poor physical functioning before treatment, in particular, are associated with worse tolerance of chemotherapy among patients with early breast cancer.Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - January 31, 2023 Category: OBGYN Tags: Hematology-Oncology News Source Type: news

Chemo in Afternoon Works Better Than in Morning, but Only in Women Chemo in Afternoon Works Better Than in Morning, but Only in Women
For women with diffuse large B-cell lymphoma undergoing chemotherapy, survival was better with less toxicity when the drugs were administered in the afternoon than in the morning.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study Shows Opdivo, Yervoy Effective After Mesothelioma Surgery
This study tested the safety and efficacy of two drugs following mesothelioma surgery after cancer recurrence. The combination of immunotherapy drugs nivolumab and ipilimumab, known by the brand names Opdivo and Yervoy, was recently approved for mesothelioma.  The new treatment led to a 6-month survival of 87% in pleural mesothelioma patients. The 12-month survival rate was 74.2%.  “Nivolumab with ipilimumab has promising efficacy in treating recurrent MPM [malignant pleural mesothelioma] in the postoperative setting,” the authors wrote. The authors also noted a higher rate of adverse events than in prior s...
Source: Asbestos and Mesothelioma News - January 30, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news

ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies
(MedPage Today) -- The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 27, 2023 Category: Hematology Source Type: news

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

FDA OKs Adjuvant Pembrolizumab for NSCLC
(MedPage Today) -- The FDA has approved pembrolizumab (Keytruda) as an adjuvant therapy following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer (NSCLC), Merck announced. The... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 27, 2023 Category: American Health Source Type: news

A 24-year-old says she'ignored' her bloating and stomach pain until it got so bad she went to the ER. Doctors diagnosed her with ovarian cancer
Doctors arranged an ultrasound scan for Chloe Etheridge (not pictured), which found two tumors on her ovaries. Getty Images A woman, 24, found out she had ovarian cancer after her stomach pain got so bad she went to the ER. Doctors arranged for an ultrasound scan, which found two tumors on Chloe…#chloeetheridge #etheridge #swns #southwestnewsservice #ovarian #cdc #chemotherapy #acs (Source: Reuters: Health)
Source: Reuters: Health - January 27, 2023 Category: Consumer Health News Source Type: news

FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Enkyboys' Randy Gonzalez told fans chemo was " not working " before his death
Randy Gonzalez, one half of the popular duo in the Enkyboys TikTok account, told fans his chemotherapy wasn't working just weeks before he died. Gonzalez passed away on Wednesday at age 35, a little more than a year after being diagnosed with colon cancer. The Enkyboys duo of Randy and his son…#randygonzalez #enkyboys #tiktok #gonzalez #brice #vivienacevedofonse #christopherperez #blackpanther #chadwickboseman #colorectal (Source: Reuters: Health)
Source: Reuters: Health - January 26, 2023 Category: Consumer Health News Source Type: news